Hayden Michael R bought 5,000 shares of IONIS PHARMACEUTICALS INC at $29.64 for $148k on Nov 10, 2026

Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
Director
DIR
Filed Nov 13, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$148,200Shares × reported price
Shares traded
5,000Common Stock
Price per share
$29.64Reported price. Read footnotes for ranges.
% of reported position traded
22.73%This security and ownership context
Holdings after
27,000Indirect · by Spouse
Trade date
Nov 10, 2026Buy
Filed
Nov 13, 2026, 4:19 PM ET3-day reporting delay
Accession
0000874015-26-000273Code P · Transaction 400657
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 22,000 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

IONS price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
IONS · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 20, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +56%1w ago +39%1d ago +6.7%
Returns since7d30d90d180d1y

Footnotes in full

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $29.60 to $29.68 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) on this Form 4. F2: The number of securities indirectly owned by the reporting person was reported as 24,000 shares on the Form 4 filed July 31, 2026. The correct number of securities indirectly owned by the reporting person as of July 31, 2026, was 22,000 shares. The amount reported on this Form 4 reflects the reporting person's correct indirect beneficial ownership.